Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[III. Immune Checkpoint Inhibitor as a Standard Treatment against Lung Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Aug 2017

Otsuka Kenji, Nishioka Yasuhiko

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Immune Evasion
Share to Immunotherapy
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Source

Identifiers

PMID: 28860436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[III. Immune Checkpoint Inhibitor as a Standard Treatment against Lung Cancer].PMID 28860436Read ↗

[IV. Development and Future Perspective of Immune Checkpoint Blockade Therapy].Semantic proximity Read ↗

[Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].Semantic proximity Read ↗

[Responses to targeted therapies: lung cancer].Semantic proximity Read ↗

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

[Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].Semantic proximity Read ↗

[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].Semantic proximity Read ↗

Cancer. A bull's eye for targeted lung cancer therapy.Semantic proximity Read ↗

[113th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Molecular Target Therapy for Lung Cancer].Semantic proximity Read ↗

[Difference in Chemotherapy for Lung Cancer between Asian and Caucasian].Semantic proximity Read ↗

[The Latest Information on Respiratory Disease Management. Topics: VII. Developments of Chemotherapy and Improvements of Prognosis in Lung Cancer].Semantic proximity Read ↗

[Targeted therapy in EGFR-mutated lung cancer following chemoradiotherapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.